Bachem Holding AG Market Cap ($5.42 Billion)
Market Cap & Net Worth: Bachem Holding AG (BANB)
Bachem Holding AG market cap. Bachem Holding AG (SW:BANB) has a market capitalization of $5.42 Billion (CHF4.29 Billion) as of October 30, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #3304 globally and #50 in its home market, demonstrating a 0.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bachem Holding AG's stock price CHF84.35 by its total outstanding shares 74935540 (74.94 Million).
Bachem Holding AG Market Cap History (2015–2026)
Bachem Holding AG market cap history from 2015 to 2026. Data shows growth from $868.97 Million to $7.99 Billion (22.68% CAGR). Check Bachem Holding AG (BANB) share price today for real-time trading data and today's change.
Bachem Holding AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bachem Holding AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see BANB operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
8.16x
Bachem Holding AG's market cap is 8.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
38.14x
Bachem Holding AG's market cap is 38.14 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.57 Billion | $236.48 Million | $41.20 Million | 6.62x | 38.00x |
| 2017 | $2.73 Billion | $261.61 Million | $41.77 Million | 10.42x | 65.28x |
| 2018 | $2.06 Billion | $282.50 Million | $46.64 Million | 7.28x | 44.09x |
| 2019 | $2.87 Billion | $313.71 Million | $54.16 Million | 9.14x | 52.91x |
| 2020 | $7.37 Billion | $402.00 Million | $78.06 Million | 18.33x | 94.41x |
| 2021 | $13.39 Billion | $503.23 Million | $114.68 Million | 26.61x | 116.75x |
| 2022 | $7.50 Billion | $531.74 Million | $100.68 Million | 14.10x | 74.46x |
| 2023 | $6.13 Billion | $577.32 Million | $111.86 Million | 10.61x | 54.78x |
| 2024 | $5.49 Billion | $605.26 Million | $120.25 Million | 9.06x | 45.62x |
| 2025 | $5.67 Billion | $695.07 Million | $148.79 Million | 8.16x | 38.14x |
Competitor Companies of BANB by Market Capitalization
Companies near Bachem Holding AG in the global market cap rankings as of October 30, 2026. See debt-free asset ratio of Bachem Holding AG to understand what proportion of total assets are financed by equity.
Key companies related to Bachem Holding AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Bachem Holding AG (2015–2026)
Market capitalization of Bachem Holding AG from 2015 to today. Between 2015 and today, Bachem Holding AG's market cap moved from $868.97 Million to $ 7.99 Billion, with a yearly change of 22.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF7.99 Billion | +40.82% |
| 2025 | CHF5.67 Billion | +3.45% |
| 2024 | CHF5.49 Billion | -10.47% |
| 2023 | CHF6.13 Billion | -18.27% |
| 2022 | CHF7.50 Billion | -44.01% |
| 2021 | CHF13.39 Billion | +81.68% |
| 2020 | CHF7.37 Billion | +157.15% |
| 2019 | CHF2.87 Billion | +39.37% |
| 2018 | CHF2.06 Billion | -24.58% |
| 2017 | CHF2.73 Billion | +74.16% |
| 2016 | CHF1.57 Billion | +80.17% |
| 2015 | CHF868.97 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Bachem Holding AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.42 Billion USD |
| MoneyControl | $5.42 Billion USD |
| MarketWatch | $5.42 Billion USD |
| marketcap.company | $5.42 Billion USD |
| Reuters | $5.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bachem Holding AG
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commerci… Read more